Company Watch

Wockhardt to launch anti-epileptic injection

Our News Bureau - Mumbai

Wockhardt received tentative approval from the USFDA for marketing Fosphenytoin injections containing 50 mg Phenytoin equivalents. This injectible is used for treating complicated forms of epileptic seizures, where oral medicines cannot be administered. Wockhardt USA will be launching the Fosphenytoin injections in the US on August 6, 2007; a day after the patent expires on August 5. Fosphenytoin is the generic name for the brand Cerebyx, sold in the US by Eisai and Pfizer. As per IMS, the US market for Fosphenytoin injection is about $73 million. "Fosphenytoin will be our third product to be launched on the first day after patent expiry. It is a very significant addition to our sterile portfolio for the US market. Now with six injections being marketed by us, our varied portfolio will enable us to expand our presence in the United States," said Habil Khorakiwala, Chairman, Wockhardt.